Cutaneous Lymphoma (CL)

Cutaneous lymphoma (CL) is a collection of lymphoproliferative disorders with a primary distribution in the skin. Protheragen is at the forefront of advancing diagnostics and therapeutics for cutaneous lymphomas. Our comprehensive services encompass the development of state-of-the-art diagnostic tools and innovative therapeutic strategies.

Overview of Cutaneous Lymphoma (CL)

Cutaneous lymphoma (CL) is a heterogeneous assortment of skin lymphoproliferative disorders that occur as extranodal non-Hodgkin lymphomas. The disease presents with numerous clinical forms, with some being more insidious and chronic and others quite aggressive and potentially lethal. These lymphomas are referred to as primary cutaneous lymphomas if confined to the skin and secondary cutaneous lymphomas if there is some systemic or nodal involvement. The World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC) jointly publish cancer classification systems for further guidance on diagnosis and therapeutics. The primary cutaneous T-cell lymphomas (CTCL) are the most commonly occurring subtype, followed in frequency by primary cutaneous B-cell lymphomas (CBCL).

Fig.1 A subset of primary cutaneous marginal zone lymphoproliferative disorders is IgM positive. (Goodlad J. R., et al., 2023)

Diagnostics Development for Cutaneous Lymphoma (CL)

Histological and Immunohistological Diagnostics

The histological analysis of skin biopsy samples remains an integral part of cutaneous lymphoma (CL) diagnostics. This includes looking at tissues under the microscope to find distinguishing morphological features pertaining to the lymphoma cells. Further cell characterization is achieved through the application of immunohistological stains, which identify cellular surface markers, like CD3 for T-cells and CD20 for B-cells, as well as some intracellular proteins, like TCR-γ/δ, which is specific for γ/δ T-cell lymphomas. With these techniques, differentiating and diagnosing the CL subtypes and other skin disorders is more accurate.

Molecular Biological Diagnostics

Molecular diagnostics are pivotal in defining and predicting the clinical trajectory of cutaneous lymphomas. Advanced methods like polymerase chain reaction (PCR) are capable of identifying clonal rearrangements of T-cell receptor (TCR) or immunoglobulin genes. This confirms the existence of a monoclonal lymphoid population. Moreover, next-generation sequencing (NGS) provides the capability to discover particular genetic alterations and chromosomal changes that are important in the selection of a targeted therapy, which increases therapeutic precision. An example of this would be the identification of JAK2 mutations or MYD88 L265P mutations in primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), which would influence the therapeutic approach.

Therapeutics Development for Cutaneous Lymphoma (CL)

• Topical Therapies: First-line for early-stage cutaneous T-cell lymphomas. Include corticosteroids (reduce inflammation/itching), chemotherapy agents (e.g., mechlorethamine), retinoids (e.g., bexarotene gel), and phototherapy (UVB/PUVA). Aim to control symptoms and prevent progression.
• Systemic Therapies: Used for advanced/disseminated cases. Include interferon-alpha (boosts immune response), retinoids (e.g., bexarotene), HDAC inhibitors (e.g., vorinostat, romidepsin), and monoclonal antibodies (e.g., mogamulizumab, brentuximab vedotin). Target molecular pathways and show efficacy in refractory/advanced cases.
• Targeted & Immunotherapies: JAK inhibitors (e.g., ruxolitinib) are effective for MF/SS. Immunotherapies (e.g., pembrolizumab) have been explored to harness the immune system. Offer hope for refractory/relapsed disease.

Table 1. Potential drivers of itch and therapeutic targets for the treatment of pruritus in cutaneous T-cell lymphomas (CTCL). (Hu M., et al., 2023)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen offers a wide range of services to support the development of diagnostics and therapeutics for cutaneous lymphomas. Our histological and immunohistological diagnostics provide detailed pathological insights, while our molecular diagnostics offer comprehensive genetic profiling. Our preclinical research services include target identification, validation, and preclinical testing, ensuring that our clients have a solid foundation for their research.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service

Therapeutic Development

• Anticancer Peptide
• Gene Therapy
• Immunotherapy
• Monoclonal Antibody
• Small Molecule Drug
• Phytotherapy
• Therapeutic Cancer Vaccine

Disease Models

• MBL2 T Lymphoma Cell Models
• Socs1 Knockout Mouse Models
• IL-15 Transgenic Mouse Models
• Patient-Derived Xenograft (PDX) Models

Protheragen's advantage lies in our comprehensive and integrated approach to diagnostics and therapeutics development. Our state-of-the-art facilities and experienced team of scientists enable us to deliver cutting-edge solutions for the complex challenges posed by cutaneous lymphomas. If you are interested in our services, please feel free to contact us.

References

• Goodlad, J. R., L. Cerroni, and S. H. Swerdlow. "Recent advances in cutaneous lymphoma—implications for current and future classifications." Virchows Archiv 482.1 (2023): 281-298.
• Dippel, Edgar, et al. "S2k-Guidelines–Cutaneous lymphomas (ICD10 C82‐C86): Update 2021." Journal der Deutschen Dermatologischen Gesellschaft 20.4 (2022): 537.
• Hu, Man, et al. "An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma." Clinical and Experimental Medicine 23.8 (2023): 4177-4197.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.